» Articles » PMID: 12966511

Prognostic Significance of Tumor Angiogenesis, Ki 67, P53 Oncoprotein, Epidermal Growth Factor Receptor and HER2 Receptor Protein Expression in Undifferentiated Nasopharyngeal Carcinoma--a Prospective Study

Overview
Journal Head Neck
Date 2003 Sep 11
PMID 12966511
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study prospectively examines the prognostic role of p53 oncoprotein (p53), Ki67-antigen (Ki67), tumor angiogenesis (MVD), epidermal growth factor receptor (EGFR), and HER2 receptor protein (HER2) expression in Chinese with undifferentiated nasopharyngeal carcinoma (NPC).

Methods: Seventy-eight Chinese were recruited from October 1995 to July 1997 at the Prince of Wales Hospital, Hong Kong. Pretreatment immunohistochemical preparations of the primary tumor were made, and clinical data were collected prospectively until October 30, 2000. The markers were correlated with overall survival (OS), disease-free survival (DFS), time to progression (TTP), and UICC stage.

Results: On univariate analysis, EGFR expression correlated with poorer OS (p =.0001), DFS (p =.01), shorter TTP (p =.0001), and advanced T stage (p =.036). Strong EGFR expression, when compared with weak or moderate, was associated with poorer OS (p =.04) and shorter TTP in a subgroup of patients with UICC stage III-IV disease. HER2 expression was associated with advanced UICC stage (p =.006). The presence of p53 expression correlated with poorer DFS (p =.01) and a trend toward shorter TTP (p =.06). No correlation was found with Ki67-antigen or MVD. On multivariate analysis, only EGFR expression was significantly linked to shorter OS and TTP.

Conclusions: EGFR expression in undifferentiated NPC is associated with a poor clinical outcome. A prognostic role of p53 and HER2 expression is suggestive but not consistently defined in this study. The relatively high prevalence of positive staining for EGFR supports the use of molecular targeted therapy in this disease.

Citing Articles

Predicting progression-free survival using dynamic contrast-enhanced imaging-based radiomics in advanced nasopharyngeal carcinoma patients treated with nimotuzumab.

Jin X, Li W, Guo Y, Wu G, Huang W, Chen F Eur Radiol. 2025; .

PMID: 39953153 DOI: 10.1007/s00330-025-11433-3.


EBV-induced upregulation of CD55 reduces the efficacy of cetuximab treatment in nasopharyngeal carcinoma.

Zhu Q, Duan X, Hu H, You R, Xia T, Yu T J Transl Med. 2024; 22(1):1111.

PMID: 39695702 PMC: 11653747. DOI: 10.1186/s12967-024-05822-3.


Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma.

Kamara S, Wen H, Guo Y, Liu Y, Liu L, Du W Cells. 2024; 13(22).

PMID: 39594573 PMC: 11592995. DOI: 10.3390/cells13221823.


In silico prediction of the action of bromelain on PI3K/Akt signalling pathway to arrest nasopharyngeal cancer oncogenesis by targeting phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha protein.

Shamsuri A, Sim E BMC Res Notes. 2024; 17(1):346.

PMID: 39593139 PMC: 11600585. DOI: 10.1186/s13104-024-06995-2.


Expression of vascular endothelial growth factor receptor-2, epidermal growth factor receptor, cyclooxygenase-2, survivin, E-cadherin and Ki-67 in canine nasal carcinomas and sarcomas - a pilot study.

Pauly L, Junginger J, Oechtering G, Hewicker-Trautwein M, Rosch S Front Vet Sci. 2024; 11:1388493.

PMID: 39268521 PMC: 11391428. DOI: 10.3389/fvets.2024.1388493.